Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 44Neoplasms, Plasma Cell 10Neoplasms 3Vomiting 2Recurrence 2Lung Neoplasms 2Prostatic Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Nausea 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Kidney Neoplasms 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Disease 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Cyclophosphamide 3Epirubicin 2Docetaxel 2Carboplatin 2Capecitabine 2Azacitidine 2venetoclax 1tegafur-gimeracil-oteracil 1taxane 1sargramostim 1ruxolitinib 1rucaparib 1pirarubicin 1pertuzumab 1pembrolizumab 1olaparib 1cc-486 1Trastuzumab 1Thalidomide 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Oxaliplatin 1Observation 1Nivolumab 1Monatide (IMS 3015) 1Methotrexate 1Magnetic Resonance Imaging 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Pathologic Complete Response × Thalidomide × Clear all
NCT01134484 2012-07-20

VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Phase 3 Unknown
480 enrolled
Plasma cell

Pathologic Complete Response, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡